Ixaka
Ixaka is a London-based, privately held cell and gene therapy company founded in 2015 that develops regenerative cell-based treatments targeting Critical Limb Ischemia and Acute Pancreatitis, serving patients with severe vascular and inflammatory conditions where current therapeutic options are limited.
- Company typePrivate
- Founded2015
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ixaka does
Ixaka is a privately held cell and gene therapy company founded in 2015 and headquartered in London, United Kingdom. The company is focused on developing therapies that leverage the body's natural capacity to cure disease, operating in the regenerative medicine space across two disclosed therapeutic indications: Critical Limb Ischemia (CLI), a severe form of peripheral artery disease, and Acute Pancreatitis, an inflammatory condition of the pancreas. These indications represent markets valued at $1,845M and $722M respectively in 2023 across the 7MM (United States, EU4, UK, and Japan), according to third-party market research referenced in the source data.
The company operates with a workforce of 51–100 employees and a full executive leadership team spanning CEO, Chairman, Vice Chairman, and functional CXO roles including Chief Medical, Scientific, Financial, Information, and Manufacturing Officers, alongside a regional Managing Director for Iberia. This organizational structure is consistent with a clinical-stage biotech advancing toward later-stage trials and commercial supply readiness. The underlying technology platform is cell-based, built around the principle of mobilizing endogenous repair mechanisms, though specific platform architecture and clinical-stage asset details are not disclosed in the available source material.
Ixaka's business model is currently pre-commercial. Revenue mechanics are not disclosed, and no pricing model, product launches, or customer relationships are reported in the source data. The company has been capitalized through approximately $72.7M in cumulative funding across five rounds between 2015 and 2021, with primary backer ZenPharma Limited leading the largest rounds and Innovate UK providing non-dilutive grant funding. As a clinical-stage biotech, the company's value-creation path runs through clinical trial progression, regulatory milestones, and eventual commercialization or partnership/out-licensing of its therapeutic candidates.
Ixaka firmographics
Firmographics- Name
- Ixaka
- Website
- https://ixaka.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Ixaka is a London-based, privately held cell and gene therapy company founded in 2015 that develops regenerative cell-based treatments targeting Critical Limb Ischemia and Acute Pancreatitis, serving patients with severe vascular and inflammatory conditions where current therapeutic options are limited.
- Ownership category
- akta.pro rank
Ixaka industry classification
Industry- Product category
- Cell and Gene Therapy / Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
Keywords
Where Ixaka is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Ixaka business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Ixaka product offering
Product offeringCore offering
Ixaka develops proprietary cell and gene therapies aimed at leveraging the body's natural ability to cure disease, with a focus on regenerative treatments for vascular and inflammatory conditions. Its pipeline targets Critical Limb Ischemia and Acute Pancreatitis, indications where current therapeutic options are limited and unmet medical need is high.
Differentiator
Problem solved
Functional benefit
Products and services
- Cell Therapy for Critical Limb Ischemia
Companies that use Ixaka
Customer profileSegments2 records
Ideal customer profiles2 records
Ixaka technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ixaka partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- DelveInsightminorDelveInsight published a market research report on Critical Limb Ischemia that references Ixaka as one of the companies operating in this therapeutic space. The market report valued the CLI market at USD 1,845 million in 2023 with projections for significant growth through 2034 driven by increasing disease prevalence and a rich pipeline of emerging therapies.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Ixaka competitors and assessment
Company assessmentDirect peers
- Hemostemix: Clinical-stage cell therapy company developing autologous stem cell treatments for Critical Limb Ischemia; directly named alongside Ixaka in the CLI competitive landscape.
- Caladrius Biosciences: Cell therapy company with programs in ischemic conditions including CLI; operates in the same regenerative medicine space as Ixaka.
- Vericel Corporation: Commercial-stage cell therapy company listed as a competitor in the CLI market; serves as a benchmark for Ixaka's potential commercial trajectory.
- Helixmith: Gene and cell therapy company referenced alongside Ixaka in the CLI therapeutic space; comparable in stage and modality.
- Mesoblast: Commercial-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular conditions; directly comparable platform technology.
- Athersys: Clinical-stage cell therapy company developing MultiStem for ischemic and inflammatory conditions including CLI; closely comparable target indications.
- Pluristem Therapeutics: Cell therapy company using placenta-derived stem cells for peripheral artery disease and CLI; direct comparator in the vascular regenerative space.
- Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplants for vascular and neurological conditions; similar platform approach and stage.
Broad incumbents
- Baxter International: Large medical products company with cell therapy and regenerative medicine interests in CLI; provides scale and distribution capabilities that Ixaka lacks.
Emerging players
- Cytori Therapeutics (now Plus Therapeutics): Cell therapy company historically developing adipose-derived regenerative cells for CLI; relevant historical comparator in the same indication.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Ixaka social profiles
Digital presenceIxaka financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ixaka leadership team
Management profileNumber of profiles
Profiles9 records
Ixaka funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ixaka M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ixaka
What does Ixaka do?
Ixaka develops proprietary cell and gene therapies aimed at leveraging the body's natural ability to cure disease, with a focus on regenerative treatments for vascular and inflammatory conditions. Its pipeline targets Critical Limb Ischemia and Acute Pancreatitis, indications where current therapeutic options are limited and unmet medical need is high.
Is Ixaka a public or private company?
Ixaka is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ixaka founded?
Ixaka was founded in 2015. It employs 51 to 100 people.
Where is Ixaka based?
Ixaka is headquartered in London, United Kingdom, in the Europe region.
Who are Ixaka's main competitors?
Direct peers on record are Hemostemix, Caladrius Biosciences, Vericel Corporation, Helixmith, Mesoblast, Athersys, Pluristem Therapeutics and Lineage Cell Therapeutics. Baxter International is listed as a broad incumbent. Cytori Therapeutics (now Plus Therapeutics) is listed as an emerging player.
Does Ixaka have an API?
No public API is recorded for Ixaka.
What industry is Ixaka in?
Ixaka's product category is Cell and Gene Therapy / Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.